Your browser doesn't support javascript.
loading
HtrA1 Mediated Intracellular Effects on Tubulin Using a Polarized RPE Disease Model.
Melo, Esther; Oertle, Philipp; Trepp, Carolyn; Meistermann, Hélène; Burgoyne, Thomas; Sborgi, Lorenzo; Cabrera, Alvaro Cortes; Chen, Chia-Yi; Hoflack, Jean-Christophe; Kam-Thong, Tony; Schmucki, Roland; Badi, Laura; Flint, Nicholas; Ghiani, Zeynep Eren; Delobel, Fréderic; Stucki, Corinne; Gromo, Giulia; Einhaus, Alfred; Hornsperger, Benoit; Golling, Sabrina; Siebourg-Polster, Juliane; Gerber, Francoise; Bohrmann, Bernd; Futter, Clare; Dunkley, Tom; Hiller, Sebastian; Schilling, Oliver; Enzmann, Volker; Fauser, Sascha; Plodinec, Marija; Iacone, Roberto.
Affiliation
  • Melo E; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland. Electronic address: esther.melo@roche.com.
  • Oertle P; Biozentrum and the Swiss Nanoscience Institute, University of Basel, Basel 4056, Switzerland.
  • Trepp C; Department of Ophthalmology, Department of Clinical Research, Inselspital, Bern University Hospital, University of Bern, Bern 3010, Switzerland.
  • Meistermann H; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland.
  • Burgoyne T; Institute of Ophthalmology, University College London, London EC1V9EL, United Kingdom.
  • Sborgi L; Biozentrum and the Swiss Nanoscience Institute, University of Basel, Basel 4056, Switzerland.
  • Cabrera AC; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland.
  • Chen CY; Institute of Molecular Medicine and Cell Research, University of Freiburg, Freiburg D-79104, Germany.
  • Hoflack JC; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland.
  • Kam-Thong T; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland.
  • Schmucki R; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland.
  • Badi L; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland.
  • Flint N; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland.
  • Ghiani ZE; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland.
  • Delobel F; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland.
  • Stucki C; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland.
  • Gromo G; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland.
  • Einhaus A; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland.
  • Hornsperger B; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland.
  • Golling S; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland.
  • Siebourg-Polster J; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland.
  • Gerber F; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland.
  • Bohrmann B; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland.
  • Futter C; Institute of Ophthalmology, University College London, London EC1V9EL, United Kingdom.
  • Dunkley T; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland.
  • Hiller S; Biozentrum and the Swiss Nanoscience Institute, University of Basel, Basel 4056, Switzerland.
  • Schilling O; Institute of Molecular Medicine and Cell Research, University of Freiburg, Freiburg D-79104, Germany; BIOSS Centre for Biological Signaling Studies, University of Freiburg, Freiburg D-79104, Germany.
  • Enzmann V; Department of Ophthalmology, Department of Clinical Research, Inselspital, Bern University Hospital, University of Bern, Bern 3010, Switzerland.
  • Fauser S; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland.
  • Plodinec M; Biozentrum and the Swiss Nanoscience Institute, University of Basel, Basel 4056, Switzerland. Electronic address: marija.plodinec@unibas.ch.
  • Iacone R; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland. Electronic address: roberto.iacone47@gmail.com.
EBioMedicine ; 27: 258-274, 2018 Jan.
Article in En | MEDLINE | ID: mdl-29269042
ABSTRACT
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss. The protein HtrA1 is enriched in retinal pigment epithelial (RPE) cells isolated from AMD patients and in drusen deposits. However, it is poorly understood how increased levels of HtrA1 affect the physiological function of the RPE at the intracellular level. Here, we developed hfRPE (human fetal retinal pigment epithelial) cell culture model where cells fully differentiated into a polarized functional monolayer. In this model, we fine-tuned the cellular levels of HtrA1 by targeted overexpression. Our data show that HtrA1 enzymatic activity leads to intracellular degradation of tubulin with a corresponding reduction in the number of microtubules, and consequently to an altered mechanical cell phenotype. HtrA1 overexpression further leads to impaired apical processes and decreased phagocytosis, an essential function for photoreceptor survival. These cellular alterations correlate with the AMD phenotype and thus highlight HtrA1 as an intracellular target for therapeutic interventions towards AMD treatment.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tubulin / Cell Polarity / Retinal Pigment Epithelium / High-Temperature Requirement A Serine Peptidase 1 / Macular Degeneration / Models, Biological Limits: Adult / Humans Language: En Journal: EBioMedicine Year: 2018 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tubulin / Cell Polarity / Retinal Pigment Epithelium / High-Temperature Requirement A Serine Peptidase 1 / Macular Degeneration / Models, Biological Limits: Adult / Humans Language: En Journal: EBioMedicine Year: 2018 Type: Article